恩瑞格要注意什么事项？

(Deferasirox) chemical name is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a 6 As a first-line drug for patients with thalassemia iron overload over the age of 18, clinical research is currently underway in China; Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce iron load in the heart and liver, and is easily accepted by patients. At the same time, it also has pharmaceutical properties such as antifungal (such as Mucor that grows in an iron-rich environment), anti-cell proliferation, anti-malarial, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis, etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.

What should patients pay attention to when using Deferasirox?

1. Warning: Kidney, liver failure and/or gastrointestinal bleeding.

2. Deferasirox may cause: kidney damage: including renal failure; liver damage: including liver failure; gastrointestinal bleeding. In some reported cases, these reactions can be fatal. The above reactions are more common in patients with advanced age, high-risk myelodysplastic syndrome (MDS), basic renal or liver damage, or low platelets (<50*10 9/L>).

3. Children under 6 years old should use Enrige with caution. Not suitable for use by children under 2 years old.

4. Avoid combination with strong inducers of UDP-glucuronosyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors) and cholestyramine.

5. It cannot be administered at the same time as aluminum-containing antacids. Not to be combined with other iron chelation treatments.

6. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Pause at least 5 days before performing Gallium-67 imaging.